Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that has completed Phase II clinical trials for the treatment of post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, bi-hormonal artificial pancreas closed-loop systems, congenital hyperinsulinism, and hypoglycemia-associated autonomic failure; and hypoglycemia associated with intermittent and chronic conditions. In addition, it develops ready-to-use diazepam formulation, which is in Phase Ib clinical trial for the treatment of Dravet syndrome and acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is Phase II clinical trials for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is headquartered in Chicago, Illinois.
IPO Year: 2018
Exchange: NASDAQ
Website: xerispharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2025 | $9.00 | Overweight | Barclays |
| 8/12/2025 | $10.00 | Buy | H.C. Wainwright |
| 11/11/2024 | $3.00 | Overweight → Neutral | Piper Sandler |
| 3/28/2024 | $5.00 | Outperform | Oppenheimer |
| 8/28/2023 | $4.50 | Buy | Craig Hallum |
| 10/21/2022 | $4.00 | Buy | Jefferies |
| 4/28/2022 | $6.50 | Buy | Craig Hallum |
| 2/16/2022 | $8.00 → $6.00 | Outperform | SVB Leerink |
| 12/31/2021 | $6.00 → $8.00 | Outperform | SVB Leerink |
| 12/31/2021 | $4.25 → $5.40 | Buy | HC Wainwright & Co. |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
3 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Barclays initiated coverage of Xeris Biopharma with a rating of Overweight and set a new price target of $9.00
H.C. Wainwright resumed coverage of Xeris Biopharma with a rating of Buy and set a new price target of $10.00
Piper Sandler downgraded Xeris Biopharma from Overweight to Neutral and set a new price target of $3.00
Oppenheimer initiated coverage of Xeris Biopharma with a rating of Outperform and set a new price target of $5.00
Craig Hallum initiated coverage of Xeris Biopharma with a rating of Buy and set a new price target of $4.50
Jefferies initiated coverage of Xeris Biopharma with a rating of Buy and set a new price target of $4.00
Craig Hallum initiated coverage of Xeris Biopharma with a rating of Buy and set a new price target of $6.50
SVB Leerink reiterated coverage of Xeris Biopharma Holdings with a rating of Outperform and set a new price target of $6.00 from $8.00 previously
SVB Leerink reiterated coverage of Xeris Biopharma Holdings with a rating of Outperform and set a new price target of $8.00 from $6.00 previously
HC Wainwright & Co. reiterated coverage of Xeris Biopharma Holdings with a rating of Buy and set a new price target of $5.40 from $4.25 previously
8-K - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
144 - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
8-K - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
8-K - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
8-K - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
144 - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
144 - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
144 - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
144 - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
10-Q - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
Fastest customizable press release news feed in the world
Please replace the release issued earlier today with the following corrected version that provides additional information regarding the inducement grants. The corrected release reads: XERIS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2026, the Compensation Committee of Xeris’ Board of Directors granted a non-qualified stock option and restricted stock units for an aggregate of 221,323 shares of its common stock to 47 new employee
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2026, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 221,323 shares of its common stock to 47 new employees under Xeris’ Inducement Equity Plan. Xeris’ Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or on
Chief Executive Officer John Shannon named Chair of the Board Marla Persky to transition to Lead Independent Director of the Board Board appoints Nerissa Kreher, M.D., effective July 1, 2026 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that its Board of Directors appointed John Shannon to Chair of the Board, in addition to his role as Chief Executive Officer, effective July 1, 2026. Mr. Shannon succeeds Marla Persky, who will remain on the Board as Lead Independent Director. The Company also announced the appo
Patent expected to provide intellectual property protection for Keveyis through 2039 Reinforces Xeris' commitment to the primary periodic paralysis community and the patients who rely on Keveyis Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, announced that today the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance with respect to U.S. Patent Application No. 17/151,405, entitled "Compositions and Methods of Use." The allowed claims in this applic
Eliminates approximately $23 million of debt, resulting in approximately $2 million in annual interest savings Principal to be paid in cash, remainder in common stock Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 8.00% Convertible Senior Notes due 2028 (the "Notes"). Pursuant to the exchange agreements, Xeris has agreed, subject to customary closing conditions, to retire approximately $23 million aggregate princi
Total product revenue increased 43% year-over-year to over $82 million Recorlev net revenue increased 95% year-over-year to $50 million Tightens full-year 2026 total revenue guidance to $380 million to $390 million Hosts conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2026. "We are thrilled with our outstanding start to 2026, delivering first quarter net product revenue growth of 43%, reflecting the succe
Conference Call to be Held at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2026 financial results before the open of the U.S. financial markets on Thursday, May 7, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. Interested parties may pre-register for the call here or via the "Events" section of the Investor Relations website. It is recommended that
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on April 1, 2026, the Compensation Committee of Xeris' Board of Directors granted restricted stock units for an aggregate of 304,975 shares of its common stock to 90 new employee(s) under Xeris' Inducement Equity Plan. Xeris' Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or
Achieved record quarterly and full-year total revenue of $86 million and $292 million, respectively Provides full year 2026 total revenue guidance range of $375 million to $390 million Hosts conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provides financial guidance for full year 2026. "Thanks to the entire Xeris organization, 2025 was a transformational year, marked by focused e
Four Orange Book Listed Patents through March 2040 Orphan Drug Exclusivity through December 2028 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, announced that its subsidiaries, Xeris Pharmaceuticals, Inc. and Strongbridge Dublin Limited, have filed a patent infringement lawsuit under the Hatch-Waxman Act related to Recorlev® (levoketoconazole) in the United States District Court for the District of New Jersey against Torrent Pharmaceuticals Limited (along with its affiliate) and Somerset Therapeutics, LLC (along with its affiliat
Live Leadership Updates
Chief Executive Officer John Shannon named Chair of the Board Marla Persky to transition to Lead Independent Director of the Board Board appoints Nerissa Kreher, M.D., effective July 1, 2026 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that its Board of Directors appointed John Shannon to Chair of the Board, in addition to his role as Chief Executive Officer, effective July 1, 2026. Mr. Shannon succeeds Marla Persky, who will remain on the Board as Lead Independent Director. The Company also announced the appo
SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ
Kenneth Johnson, PharmD, SVP Global Development & Medical Affairs to retire Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that Dr. Anh Nguyen has joined Xeris as Chief Medical Officer (CMO) succeeding Ken Johnson PharmD, SVP, Global Development and Medical Affairs who will retire April 1, 2025. Dr. Nguyen will develop and lead the entire product portfolio vision and strategic direction for the Medical, Regulatory, Preclinical and Clinical Development, and Pharmacovigilance functions, reporting to John Shannon, X
John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track record of its leadership team Q2 '24 total revenue is anticipated to exceed $47 million, representing more than 23% growth over last year Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced a CEO succession plan effective August 1, 20
Xeris Biopharma Holdings (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic areas, appointed Ricki Fairley to its Board of Directors, increasing the size of the Board to nine members, on March 27, 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230329005369/en/(Photo: Business Wire) "On behalf of our Board, we welcome Ricki and her wealth of insights and experiences, especially her passion for advocating on behalf of patients," said Paul R. Edick, Chairman and Chief Executive Officer of Xeris. "As
WOBURN, Mass.--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Jonathan Rigby has joined its Board of Directors. Mr. Rigby brings extensive company building and pipeline development experience in autoimmune and other diseases. IM Therapeutics is developing small molecule oral genetic medicines targeting specific human leukocyte antigen (HLA) variants known to play a strong role in autoimmune diseases. The Company’s lead drug candidate, IMT-002, is in Phase 1b clinical trials in type 1 diabetes (T1D). Patients in the study were preselected for HLA-DQ8, the
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (NASDAQ: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on December 30, 2020, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 38,250 shares, and restricted stock units for an aggregate of 35,100 shares, of its common stock to 7 new employee(s) under Xeris’ Inducement Equity Plan. Xeris’ Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of
This live feed shows all institutional transactions in real time.
SC 13G - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
SC 13G/A - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
SC 13G - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
SC 13G/A - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
SC 13G/A - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
SC 13G - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
SC 13G/A - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
SC 13G - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
SC 13G - XERIS PHARMACEUTICALS INC (0001346302) (Subject)
SC 13G/A - XERIS PHARMACEUTICALS INC (0001346302) (Subject)
Live finance-specific insights
Total product revenue increased 43% year-over-year to over $82 million Recorlev net revenue increased 95% year-over-year to $50 million Tightens full-year 2026 total revenue guidance to $380 million to $390 million Hosts conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2026. "We are thrilled with our outstanding start to 2026, delivering first quarter net product revenue growth of 43%, reflecting the succe
Conference Call to be Held at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2026 financial results before the open of the U.S. financial markets on Thursday, May 7, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. Interested parties may pre-register for the call here or via the "Events" section of the Investor Relations website. It is recommended that
Achieved record quarterly and full-year total revenue of $86 million and $292 million, respectively Provides full year 2026 total revenue guidance range of $375 million to $390 million Hosts conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provides financial guidance for full year 2026. "Thanks to the entire Xeris organization, 2025 was a transformational year, marked by focused e
Conference Call to be Held at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full year 2025 financial results before the open of the U.S. financial markets on Monday, March 2, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. To pre-register for the call, please go to the following link: https://events.q4inc.com/analyst/428274643?pwd=TZMrH35H Afte
Conference Call to be Held at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its third quarter 2025 financial results before the open of the U.S. financial markets on Thursday, November 6, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. To pre-register for the call, please go to the following link: https://www.netroadshow.com/events/login/LE9zwo3lV0p4Y9XVAt3dNbajZlK6unm
Total revenue increased 49% YoY to $71.5 million; Recorlev® revenue grew 136% YoY Raises full-year 2025 total revenue guidance to $280-$290 million from previous range of $260-$275 million Provided long-term outlook at Analyst and Investor Day in June Hosts conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the second quarter ended June 30, 2025, and updated its fiscal 2025 guidance. "Total revenue in the second quarter increased almost 50%
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2025 financial results before the open of the U.S. financial markets on Thursday, August 7, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. To pre-register for the call, please go to the following link: https://www.netroadshow.com/events/login/LE9zwo3gmwDLA5JeSSHtiUIAhliB0lMHV58 After registering, a confirmation email
Total revenue increased 48% YoY to over $60 million Recorlev® revenue grew 141% on YoY basis Tightens full-year total revenue 2025 guidance to $260 million to $275 million Announces upcoming Investor and Analyst Day on June 3rd in New York City Hosts conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2025, and updated its fiscal 2025 total revenue guidance. "We're very pleased with our strong start to the year,
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2025 financial results before the open of the U.S. financial markets on Thursday, May 8, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. To pre-register for the call, please go to the following link: https://www.netroadshow.com/events/login?show=7ba30d1f&confId=80481 After registering, a confirmation email will be sen
Achieved record quarterly and full-year total revenue of $60M and $203M, growing 35% and 24% versus prior year Recorlev® revenue more than doubled versus prior year and grew 28% in the fourth quarter sequentially Ended Q4 with over $71M in cash, generating $2M in cash in the fourth quarter Provides full-year 2025 total revenue guidance of $255M-$275M, representing a growth of over 30% at the mid-point of the range Hosting conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today annou